Skip to main content

Table 2 Effects of First-line Chemotherapy for Patients with ES-SCLC

From: Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer

 

ES-SCLC (n = 83)

%

Regimen

  

 CDDP + CPT

5

6

 CDDP + VP-16

3

4

 CBDCA + VP-16

20

24

 AMRa

41

49

 AMR + CPTa

9

11

 CDDP + VP-16/AMR + CPTa

5

6

Cycles

  

 1/2

11/10

13/12

 3/4

12/36

14/43

 5/6

2/12

2/14

Response

  

 Complete response

1

1

 Partial response

45

54

 Stable disease

10

12

 Progression disease

10

12

 Not evaluable

17

20

Progressionb

  

 Sensitive relapse

23

28

 Refractory relapse

60

72

Survival, median, monthsc

  

 PFS

5.0 (4.5–5.5)

-

 OS

9.2 (7.6–10.8)

-

 [OS for sensitive relapse]

[19.4 (12.9–25.9)]

-

 [OS for refractory relapse]

[6.9 (6.3–7.6)]

-

  1. Note: ES-SCLC extensive-stage small cell lung cancer, CDDP cisplatin, CBDCA carboplatin, CPT irinotecan, VP-16 etoposide, AMR amrubicin, PFS progression free survival, OS overall survival
  2. aIncluding patients in clinical trials
  3. bSensitive relapse: Relapsed three months after completion of the initial therapy, Refractory relapse: Experienced disease progression within three months
  4. c(): 95 % confidence interval